This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Veradigm (MDRX) to Acquire AI Service Provider ScienceIO
by Zacks Equity Research
Veradigm (MDRX) is set to acquire ScienceIO to benefit its Provider, Payer and Life Sciences businesses, offering highly differentiated and advanced products to its customers.
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
by Zacks Equity Research
Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.
Veradigm's (MDRX) Acquires Koha Health to Solidify Market Presence
by Zacks Equity Research
Veradigm's (MDRX) acquisition of Koha Health will likely enhance its ability to deliver efficient revenue cycle services by incorporating Musculoskeletal Medicine specialty subject matter expertise.
Braze, Inc. (BRZE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Braze, Inc. (BRZE) delivered earnings and revenue surprises of 61.54% and 5.89%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?
Veradigm's (MDRX) New Offering to Enhance Patient Engagement
by Zacks Equity Research
Veradigm's (MDRX) latest solution is likely to offer its clients the right payment option to each individual patient through the right communication channel.
Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity
by Zacks Equity Research
Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency.
Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery
by Zacks Equity Research
Veradigm's (MDRX) new phase of strategic investment is likely to drive innovation and close the evidence gap in behavioral health.
Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes
by Zacks Equity Research
Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve.
Vivid Seats Inc. (SEAT) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Vivid Seats Inc. (SEAT) delivered earnings and revenue surprises of 233.33% and 10.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Yext (YEXT) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Yext (YEXT) delivered earnings and revenue surprises of 60% and 0.90%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Sprinkler (CXM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Sprinkler (CXM) delivered earnings and revenue surprises of 500% and 2.68%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Veradigm (MDRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Veradigm (MDRX) stock based on the movements in the options market lately.
Kyndryl Holdings, Inc. (KD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kyndryl Holdings, Inc. (KD) delivered earnings and revenue surprises of 82.93% and 2.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Veradigm (MDRX) Stock for Now
by Zacks Equity Research
Veradigm (MDRX) continues to hold on to investors' interests owing to its strategic alliances.
Earnings Preview: R1 RCM Inc. (RCM) Q1 Earnings Expected to Decline
by Zacks Equity Research
R1 RCM Inc. (RCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Veradigm (MDRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Veradigm (MDRX) stock based on the movements in the options market lately.
Implied Volatility Surging for Veradigm (MDRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Veradigm (MDRX) stock based on the movements in the options market lately.
Implied Volatility Surging for Veradigm (MDRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Veradigm (MDRX) stock based on the movements in the options market lately.
What to Expect from Verisk Analytics' (VRSK) Q4 Earnings?
by Zacks Equity Research
Verisk Analytics' (VRSK) earnings and revenues are expected to have taken a hit by the disposition of parts of its energy and specialized market segments.
3 Service Stocks Poised to Beat Earnings Estimates in Q4
by Shuvra Shankar Dey
Here we pick three business service stocks, namely PagSeguro Digital (PAGS), Veradigm (MDRX) and TuSimple (TSP), which are likely to pull off earnings surprises this time around.
Green Dot (GDOT) to Report Q4 Earnings: What to Expect
by Zacks Equity Research
Green Dot's (GDOT) revenues and earnings seem to have suffered due to declining active accounts and increasing expenses.
Analysts Estimate TTEC Holdings (TTEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
TTEC (TTEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will (MDRX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
(MDRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MDRX or VERI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MDRX vs. VERI: Which Stock Is the Better Value Option?
Syneos Health (SYNH) Signs New Partnership With Cryoport
by Zacks Equity Research
Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.